Earnings

UPDATE: Tarsus Pharmaceuticals Q3 Adj. EPS $(0.78) Beats $(2.73) Estimate, Sales $194.569M Beat $186.598M Estimate

Nov 3, 2026 · 06:05 PM ET· updated 46m ago

Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(2.73) by 71.43 percent. This is a 160 percent decrease over losses of $(0.30) per share

Why It Matters

Tarsus lost less money per share than experts predicted, which is good. Sales also beat what people expected, so the business is growing.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

TARS72.60

-0.72 (-0.98%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.